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Abstract In several, but not all, previous studies, positive
p21WAF1 expression has been suggested as an indicator of a
good prognosis in patients with stage III/IV colorectal
cancer. However, it is not known whether the same is true
for stage B2 patients. The purpose of this study is to assess
the influence of p21WAF1 expression in tumor cells on
disease-free survival (DFS) and overall survival (OS) of
Astler–Coller stage B2 and C patients with colorectal
cancer who underwent 5-fluorouracil-based adjuvant che-
motherapy. Nuclear p21WAF1 was detected by immunohis-
tochemistry in tissue microarrays from 275 colorectal
cancers. The expression of p21WAF1 was associated with
DFS (p=0.025) and OS (p=0.008) in the subgroup of stage
B2 patients that was treated with adjuvant chemotherapy. In
multivariate analysis, it remained the only independent
prognostic parameter in relation to DFS and OS (p=0.035
and p=0.02, respectively). In the subgroup of 72 stage B2
patients with positive p21WAF1 expression but not in the
subgroup of 61 stage B2 patients with negative p21WAF1
expression, adjuvant chemotherapy was associated with
better DFS (85% 5-year survival versus 65% without
chemotherapy, p=0.03) and OS (96% versus 82%, p=
0.014). In the combined stage B2 and C group of patients
treated with adjuvant chemotherapy, positive p21WAF1
expression was also associated with better DFS and OS
(p=0.03, p=0.002, respectively). Expression of p21WAF1 in
colorectal tumor cells identifies a subgroup of Astler–Coller
stage B2 patients who could benefit significantly from
5FU-based chemotherapy and may improve the selection of
patients for adjuvant chemotherapy.
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Introduction
The efficacy of 5-fluorouracil (5FU)-based adjuvant che-
motherapy and the associated survival benefit have been
firmly established for patients with stage III colorectal
cancer (CRC) [1]. However, the use of adjuvant therapy for
stage II colon cancer patients remains controversial [2].
Typically, only high-risk stage II CRCs are treated. Hence,
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there is a need for predictive factors to support treatment
decisions in this group of patients, the majority of whom
will be cured by surgery alone [3]. This is especially
important because a wider implementation of prophylactic
programs in recent years has resulted in an increased
number of patients with stage B2 tumors.
5-Fluorouracil has been used to treat colorectal
cancer patients for a long time [4]. The target enzyme
for 5FU is thymidylate synthase (TS). This enzyme
catalyzes the conversion of deoxyuridine-5′monophos-
phate to deoxythymidine-5′-monophosphate and is there-
fore essential for DNA synthesis and repair. Resistance to
5FU-based treatment might depend both on the level of
expression of TS and other enzymes involved in the
metabolism of 5FU and on mechanisms involved in cell
growth or apoptosis. p21WAF1 is a multifunctional cell
cycle-related protein that inhibits cyclin-dependent
kinases (CDKs), which results in cell cycle arrest in the
G1 phase [5]. p21WAF1 expression is known to be
inversely related to cell proliferation and directly related
to terminal differentiation [6]. Recently, it has been shown
that TS expression was upregulated in p21WAF1-/- human
colorectal cancer HCT116 cells, and TS promoter activity
was downregulated by ectopic p21 expression [7]. Fur-
thermore, a CDK inhibitor reduced expression of TS in a
dose-dependent manner, and the reduction resulted in
enhancement of sensitivity to 5FU in cultured human
colon cancer cells [8]. Taken together with other reports
[9], this suggests a great importance of p21WAF1 for in
vitro response to chemotherapeutic agents and that the CDK
inhibitor p21WAF1 regulates thymineless stress-induced DNA
damage. Hence, p21WAF1 expression might have a predictive
significance in 5FU-treated CRC patients. In several [10–19]
but not all [20–24] previous studies, positive p21WAF1
expression has been suggested as an indicator of good
prognosis in patients with stage III/IV CRC. However, it is
not known whether the same is true for stage B2 patients.
Therefore, our purpose was to assess the influence of
p21WAF1 expression on disease-free survival (DFS) and
overall survival (OS) of Astler–Coller stage B2 patients with
CRC who either were or were not treated with 5FU-based
adjuvant chemotherapy, and of stage C patients treated with
adjuvant chemotherapy.
Materials and methods
Patients This retrospective study was based on tumor tissue
from 275 unselected patients who underwent potentially
curative colorectal resection for sporadic CRC (defined as
an absence of relevant family history at the time of
admission to the hospital). Distant metastases at the time
of operation were excluded by preoperative liver ultraso-
nography, chest x-ray, and intraoperative exploration.
Table 1 lists the clinico-pathological details of the 275
tumors and patients. Astler–Coller staging of CRC based on
the extent of local invasion and the status of lymph nodes
was used [25]. In this system, stage B2 denotes the tumor
penetrating through the muscularis propria and uninvolved
nodes, stage C—tumors extending into the muscularis
propria or penetrating through it with lymph node metas-
tases. The mean age of the patients was 61.1±10.8 years
(range, 33–83; median, 62). The splenic flexure was
regarded as the border between the proximal and distal
colon. The Research Ethics Committee of Pomeranian
Medical University approved this study.
Tumors were resected between July 1997 and April 2004
in the Departments of Surgery of the teaching hospitals of
Pomeranian Medical University in Szczecin and the
Regional Oncological Center in Szczecin, Poland. The
operations consisted of either a resection with lymphade-
nectomy or a total mesorectal excision for rectal carcino-
mas. A total of 203 (74%) patients (83 high-risk stage B2
and 120 stage C) were treated with adjuvant chemotherapy
(six 5-day courses of bolus infusion of 5FU (425 mg/m2)
every 4 weeks combined with leucovorin, 20 mg/m2). A
Table 1 Relations between p21WAF1 expression and clinico-
pathological parameters
Parameter p21WAF1 Expression
n n (%) p
Age (years)
<62 138 87 (63) 0.39
>62 137 79 (58)
Sex
Females 120 75 (63) 0.54
Males 155 91 (59)
Grade
G1+G2 156 91 (58) 0.46
G3a 119 75 (63)
Astler–Coller
B2 133 72 (54) 0.049
C 142 94 (66)
Site
Proximal 53 37 (70) 0.16
Distal 222 129 (58)
Site
Rectum 138 81 (59) 0.62
Colon 137 85 (62)
Radiotherapy (rectal tumors)
Preoperative 43 26 (61) 0.85
Postoperative RT and no RTb 93 53 (57)
a Including mucinous carcinoma
b Radiotherapy status unknown in two cases
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total of 72 patients (22 stage C patients) did not receive
adjuvant chemotherapy due to internist contraindications.
A total of 41 patients with rectal cancer received postop-
erative radiotherapy (50.4 Gy), and 43 patients, preoperative
radiotherapy (5×5 Gy). Of the 133 Astler–Coller stage B2
tumors, there were 65 rectal tumors, and of these, 24 (18%)
received preoperative and 11 (8.3%) received postoperative
radiotherapy. Radiotherapy did not influence DFS (p=0.61)
nor OS (p=0.83) of patients with rectal tumors. Since we did
not find a statistically significant difference in p21WAF1
expression between the group of patients subjected to
preoperative radiotherapy and the remaining 93 rectal tumors
not treated with preoperative radiotherapy (Table 1), the
former was included in the study.
Time from the surgery until the time of death due to cancer
or to last known follow-up was regarded as OS, and the time
until the first appearance of metastasis or local recurrence was
regarded as DFS. The median follow-up was 54 months
(mean, 57.3±30.5 months; range, 5–143 months). During the
follow-up, 66 of the 275 (24%) patients died of their disease,
and 165 (60%) were alive without symptoms from the disease.
Recurrences were found in 106 patients. Four patients died of
non-cancer-related causes, and they were treated as censored
observations.
Tissue microarray (TMA) construction Tumor areas with
the highest mitotic activity at the outer invasive zone of the
cancer were chosen for tissue microarrays which were
constructed as previously described [26].
Immunohistochemistry Slides with tissue microarrays were
deparaffinized, rehydrated, and had the endogenous peroxi-
dase activity blocked. Slides were immersed in pH 9.0 buffer,
and heat-induced antigen retrieval was performed in a
pressure cooker (Pascal, Dako, Glostrup, Denmark). Mono-
clonal p21WAF1 antibody (Dako) was used (dilution, 1:25;
incubation time, 30 min), and the slides were immunostained
using a Dako EnVision+ kit according to the manufacturer’s
instructions. We used the sensitive EnVision+ visualization
system because the detection system used is regarded as a
critically important variable in immunohistochemical analy-
sis, and detection methods using signal amplification with
HRP-labeled polymers have been shown to be more
sensitive than methods without such a layer of amplification
[27]. The reaction was developed with diaminobenzidine
substrate–chromogen solution, and the slides were counter-
stained with hematoxylin. Positive controls included colo-
rectal adenocarcinoma previously shown to have a high level
of p21WAF1 expression. Negative controls omitted the
primary antibody. The immunohistochemical procedure for
all tissue microarrays from 275 tumors was performed at the
same time in identical conditions because, instead of
275 histological slides of whole tissue sections, only
four slides containing tissue cores from all 275 tumors
were processed.
Scoring Immunohistochemical staining for each tumor core
was independently assessed by two observers (PD and WD)
who were blinded to the clinical and pathological data. In
cases of disagreement, the result was reached by consensus.
The percentage of tumor cell nuclei with unequivocal
staining was recorded for each core. P21WAF1 expression in
tumors was variable, and so, tumors were classified as
negative (<1% of positive tumor cells) or positive (if ≥1%
of tumor cells showed nuclear immunoreactivity).
Statistical analysis Associations between the presence of
p21WAF1 expression in tumors and other categorical
variables were analyzed with the Fisher exact test. The
Kaplan–Meier method was used for the univariate survival
analysis, and the differences between compared groups
were assessed by the log-rank test. A Cox proportional
hazards model was used for univariate and multivariate
analyses of factors associated with OS and DFS. The
independent variables included in the model were: age,
gender, tumor site, Astler–Coller stage, histological grade,
5FU-based adjuvant chemotherapy, and presence of
p21WAF1 expression. A p<0.05 was considered statistically
significant. STATISTICA version 9.1 (StatSoft Inc., Tulsa,
USA) was used for the statistical analysis.
Results
Expression of p21WAF1 (Fig. 1a–d) was found in the nuclei
of 60.4% (166/275) of all cases, in 54.1% (72/133) of stage
B2 cancers, and in 66.2% (94/142) of stage C tumors. Of
all the parameters examined, only Astler–Coller stage was
associated with p21WAF1 expression (Table 1).
Group B2 No association was found between p21WAF1
expression and DFS or OS in the whole B2 group, neither
in univariate or multivariate analysis (data not shown).
However, 83 patients in this group were treated with 5FU-
based adjuvant chemotherapy, and 50 patients were not.
Further analysis of the association of p21WAF1 expression
with DFS and OS in these subgroups showed that
expression of p21WAF1 was associated with DFS (p=
0.025) and OS (p=0.0079) only in the subgroup of stage
B2 patients that were treated with adjuvant chemotherapy
(Fig. 2a). Moreover, p21WAF1 expression remained in this
subgroup as the only independent prognostic parameter in
the multivariate analysis in relation to DFS and OS (p=
0.035 and p=0.02, respectively; Table 2). In the stage B2
subgroup of patients not treated with chemotherapy, none
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of the parameters studied were associated with DFS or OS
(data not shown).
In the subgroup of 72 stage B2 patients with p21WAF1
expression, adjuvant chemotherapy was associated with
better DFS (85% 5-year survival versus 65% without
chemotherapy, p=0.03; Fig. 2b) and OS (96% 5-year
survival versus 82% without chemotherapy, p=0.014;
Fig. 2b). In the subgroup of 61 stage B2 patients with
negative p21WAF1 expression, a trend for the association of
chemotherapy with worse survival (both DFS and OS) was
observed, but the differences were not statistically signifi-
cant (data not shown).
Group C The expression of p21WAF1 in tumors of patients
treated with adjuvant chemotherapy was associated with
DFS in a univariate analysis (HR=0.58, 95% CI=0.34–
0.99, p=0.047) and was on the verge of statistical
significance in the multivariate analysis (p=0.07) (Table 2).
In terms of OS, there was a statistically significant
association with p21WAF1 expression in both the univariate
(HR=0.41, 95% CI=0.21–0.80, p=0.008) and multivariate
(p=0.03) (Table 2) analyses. Kaplan–Meier survival curves
of patients with p21WAF1 expression in the nuclei of cancer
cells indicate better DFS (p=0.055) and significantly better
OS (72% versus 45% 5-year survival of patients with
negative p21WAF1 expression, p=0.0079; Fig. 2c).
Stage B2+C patients treated with adjuvant chemotherapy Ex-
pression of p21WAF1 was associated with DFS and OS (p=
0.03 and p=0.002, respectively) in a univariate analysis.
The Astler–Coller stage and p21WAF1 expression were
found to be independent prognostic factors for DFS and
OS (Table 3). In multivariate analysis, there was no
statistically significant association between site of CRC
Fig. 1 Expression of p21WAF1in representative cores of CRC. a, b High expression of p21WAF1 in the nuclei of tumor cells. c, d Low expression
of p21WAF1 in the nuclei of cancer cells. b, d Fragments of the cores from a and c, respectively, at high magnification
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(neither rectum versus colon nor proximal versus distal as
defined by the splenic flexure) and DFS (p=0.77, p=0.28,
respectively) or OS (p=0.77, p=0.28, respectively).
Kaplan–Meier survival curves showed significantly better
DFS and OS of patients with tumors showing p21WAF1
expression as compared to those negative for p21WAF1 (p=
0.03 and p=0.0018, respectively; Fig. 2d).
Discussion
We found p21WAF1 nuclear expression in 60.4% CRCs
which is comparable to the literature data (16–87%) [11,
13–15, 28, 29]. The majority of reports (but not all)
concerning the prognostic role of p21WAF1 expression in
CRCs indicate better OS and/or DFS for patients with
Fig. 2 DFS (black curves) and OS (red curves) of stage B2 patients
treated with adjuvant chemotherapy categorized according to the p21
expression (n=83) (a) and of stage B2 patients with p21-positive
tumors categorized according to adjuvant chemotherapy (n=72) (b).
DFS (black curves) and OS (red curves) of stage C patients (n=120)
(c) and of stage B2+C patients (n=203) (d) treated with adjuvant
chemotherapy categorized according to p21 expression
Table 2 Multivariate analysis of disease-free and overall survival of stage B2 and C patients treated with adjuvant chemotherapy
Category B2 (n=83) C (n=120)
Disease-free survival Overall survival Disease-free survival Overall survival
Hazard ratio (95% Cl) p Hazard ratio (95% Cl) p Hazard ratio (95% Cl) p Hazard ratio (95% Cl) p
Sex 0.97 (0.37–2.53) 0.95 0.99 (0.24–4.04) 0.99 1.21 (0.71–2.08) 0.49 1.50 (0.73–3.05) 0.27
Age 0.99 (0.95–1.03) 0.63 1.00 (0.94–1.07) 0.99 1.02 (0.99–1.05) 0.12 1.02 (0.99–1.05) 0.29
Grade 0.56 (0.20–1.57) 0.27 0.39 (0.08–1.86) 0.24 1.93 (1.12–3.33) 0.018 2.87 (1.37–6.01) 0.005
Tumor site 0.99 (0.29–3.47) 0.10 2.55 (0.64–10.15) 0.19 0.57 (0.27–1.17) 0.13 0.35 (0.10–1.15) 0.08
P21WAF1 0.36 (0.14–0.93) 0.035 0.16 (0.03–0.76) 0.02 0.60 (0.35–1.04) 0.07 0.48 (0.24–0.93) 0.03
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tumors showing p21WAF1 expression (Table 4). In some of
these reports, p21WAF1 expression was an independent
prognostic factor for OS and/or DFS (Table 4). However,
in those reports, patients with various stages of the disease
who were subjected to different treatment protocols
(surgery alone, surgery and adjuvant chemotherapy, radio-
chemotherapy) were often grouped together for the analy-
sis, or no information on the mode of therapy is given.
Thus, it is difficult to infer whether stage II patients with
p21WAF1-positive tumors may receive any benefit from
adjuvant chemotherapy.
The benefit of adjuvant 5FU-based chemotherapy has been
firmly established for patients with stage III CRC. However,
in the stage B2 group, it is not known whether the survival
benefit from chemotherapy is sufficient to outweigh the
toxicity and cost of the treatment [2]. Only one study [20] has
addressed the issue of the influence of 5FU-based adjuvant
chemotherapy on the survival of patients with stage B2 CRC
in relation to p21WAF1 expression. In that study, pretreatment
levels of p21WAF1 were not related to survival of patients
with stage II (and III) CRC treated with adjuvant chemo-
therapy. However, increased levels of p21WAF1 were associ-
Category Disease-free survival Overall survival
Hazard ratio (95% Cl) p Hazard ratio (95% Cl) p
Sex 1.20 (0.75–1.90) 0.44 1.42 (0.77–2.65) 0.27
Age 1.01 (0.99–1.03) 0.32 1.01 (0.98–1.04) 0.58
Astler–Coller 3.16 (1.86–5.36) <0.0001 3.60 (1.77–7.33) 0.0004
Grade 1.48 (0.94–2.32) 0.09 1.95 (1.07–3.56) 0.03
Tumor site 0.64 (0.34–1.20) 0.17 0.62 (0.26–1.49) 0.28
P21WAF1 0.52 (0.33–0.83) 0.0062 0.36 (0.20–0.66) 0.0009
Table 3 Multivariate analysis
of disease-free and overall
survival of patients treated with
adjuvant chemotherapy (group
B2+C, n=203)
Table 4 Major reports on p21WAF1 expression and survival of patients with CRCs
Source Study group Stage of CRC and type of treatment Results
Cheng J.D., et al. [10] n=39 Metastatic CRC 5FU CHTH 5FU responders had greater p21 expression
Ropponen K.M, et al. [11] n=162 0–D incl. 62–B majority: surgery
only; 22–CHTH
Better OS and RFS for patients with p21+ tumors;
p21: independent prognostic parameter for OS
and RFS (MA)
Viale G., et al. [12] n=191 I–IV CHTH? ↓p21→poor OS and DFS (UA)
Bukholm I.K., et al. [13] n=61 B–D CHTH? Low p21→ increased risk of metastases and death
Zirbes T.K., et al. [14] n=294 I–IV incl. 90–II. surgery CHTH? Better OS for patients with p21+ tumors;
p21 independent prognostic parameter (MA)
Holland T.A., et al. [15] n=126 A–D RCHTH? Better OS for patients with high p21 expression
Pasz-Walczak G., et al. [16] n=122 I–IV CHTH? Better OS for patients with p21+ tumors (UA)
Watanabe T., et al. [20] n=460 II (B)–105 III (C)–355, 5FU CHTH No association of p21 expression with survival
in all and in stage B tumors
Hoss A., et al. [21] n=100 T2–3, N0 rectum, surgery only No association of p21 expression with survival
Schwandner O., et al. [17] n=160 I–III rectum, surgery, n=69
surgery+CHTH+RT, n=91
Better RFS but not OS for patients with p21+ tumors;
p21 independent prognostic parameter for RFS
but not OS (MA)
Rau B., et al. [22] n=66 T3–4, N0–2, M0–1 rectum, RCHTH No prognostic significance of pretreatment p21
expression. Post-treatment increase of p21: shorter DFS
Prall F., et al. [18] n=184 I–IV incl. 55-III, III: n=32 -5FU,
n=23-5FU+RT
Better OS for patients with p21+tumors (MA)
Mitomi H., et al. [19] n=211 B–D incl. 83-B CHTH for C–D Better OS for patients with high p21 expression;
p21 independent prognostic parameter (MA)
Ioachim E., et al. [23] n=97 Dukes B, C, surgery, CHTH? No association of p21 expression with OS and DFS
Noske A., et al. [24] n=116 II–III RCHTH Better RFS and OS for patients with p21- tumors
↓ down regulation, UA univariate analysis, MA multivariate analysis, OS overall survival, DFS disease-free survival, RFS relapse-free survival, RT
radiotherapy, CHTH chemotherapy, RCHTH radiochemotherapy, ? not known
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ated with the sensitivity of metastatic CRC to 5FU-based
chemotherapy [10].
Our results indicate for the first time that p21WAF1
expression in CRC tumor cells is an independent factor that
is associated with favorable DFS and OS in patients with
stage B2 tumors treated with 5FU-based adjuvant chemo-
therapy. Striking survival benefits were seen for stage B2
patients who received adjuvant chemotherapy compared
with those who did not. Conversely, chemotherapy did not
significantly influence DFS or OS of stage B2 patients with
p21WAF1-negative tumors. Rather, a statistically non-
significant trend towards worse survival was observed for
stage B2 patients with p21WAF1-negative tumors treated
with chemotherapy. The differences between our results and
those of Watanabe et al. [20] may be attributed to the
different scoring systems and different cutoff points used
for the interpretation of immunohistochemical staining, as
well as to differences in immunohistochemical methods.
The major advantage of tissue microarrays is that tens of
cases can be processed in identical laboratory conditions
which greatly improves the reproducibility of the immuno-
histochemical method. Prall et al. [18] used tissue micro-
arrays (n=184) and found better OS for combined group of
stage I–IV patients with p21WAF1-positive tumors. Our
results (from the whole group) are well in accord with this
report and give further support for the association of
p21WAF1 expression and longer survival of patients with
stage C/III CRCs treated with adjuvant 5FU-based chemo-
therapy as has been reported previously (Table 4). One
limitation of TMA technology is that “punched” cores from
donor tissues may not always be representative of the entire
tumor. In this report, we applied one core from carefully
identified, histologically relatively homogenous area with
the highest mitotic activity in the outer invasive zone of
each CRC. Using this approach, we found 60.4% of
p21WAF1-positive CRCs which is within the range reported
in the literature. Hoos et al. [30] reported that correlations
between phenotypes and clinical outcome were not signifi-
cantly different between full sections and triplicate 0.6-mm
core tissue microarrays. However, on the other hand, they
were not significantly different when only one 0.6-mm core
tissue microarray was used [31]. The authors of the latter
report conclude that tissue microarray “with a single core per
specimen ensures full biological representativeness to iden-
tify the associations between biomarkers and clinico-
pathological parameters, with no significant associated
sampling bias.” So, careful sampling of the representative
region of the tumor is regarded as the key step in the
construction of tissue microarrays.
TS, the target enzyme for 5FU, is essential for DNA
synthesis [32], and it may function as an oncogene [33].
Inhibition of TS induces apoptosis and cytotoxicity in
human colorectal cancer cells [7]. The importance of
p21WAF1 in the response of CRC to chemotherapeutic
agents is supported by in vitro studies [7–9]. It has been
reported that p21WAF1 (a CDK inhibitor) regulates thymine-
less stress-induced cytotoxicity of human colon carcinoma
cell lines [7]. Also, TS expression is mediated through the
inhibition of CDK: TS expression was upregulated by the
knockout of the p21WAF1 gene in a CRC cell line [8]. In
addition, reduction of TS expression results in enhancement
of the sensitivity to 5FU in human CRC cell lines [8]. Our
results are in line with other reports that show that p21WAF1
is a critical mediator of the cytotoxic action of TS inhibitors
in cultured human colorectal cancer cells [7] and that CDK
inhibitor enhances the sensitivity to 5FU in colorectal
cancer cell lines [8]. In fact, p21WAF1 is required for
maximal cytotoxicity induced by thymineless stress in
colorectal cancer cells in culture [7]. Poor survival of
patients with p21WAF1-negative tumors treated with adju-
vant 5FU-based chemotherapy may perhaps be attributed to
inherent resistance to 5FU. It has been shown that
development of resistance to 5FU by colon cancer cell
lines is associated with downregulation of the CDKN1A
gene, along with other genes engaged in DNA damage
response/repair pathway [34].
In summary, we found that p21WAF1 expression in CRC
tumor cells identifies a subgroup of Astler–Coller stage B
patients who would benefit significantly from 5FU-based
chemotherapy and may therefore allow for better selection
of patients for adjuvant chemotherapy. We believe that, in
order to maximize the benefit of 5FU-based adjuvant
therapy and to spare patients from unnecessary toxicity,
stage B2 patients should be stratified according to p21WAF1
status. However, because this is a retrospective study, our
results should be confirmed by further prospective random-
ized investigations.
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